Sun et al. found that HBV-related HCC patients receiving IFN-α treatment after curative resection exhibited greatly improved median OS at 63.8 months in the treatment group versus 38.8 months with placebo and a 13.5 month increase in median DFS [293]. This evidence concerns the gene IFNA1 and hepatocellular carcinoma.